<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <meta name="study:id" content="dlbcl-bulgaria-davidkova">
    <meta name="study:title" content="PB3326 - Diffuse Large B-Cell Lymphoma - Single center experience in Bulgaria">
    <meta name="study:fileName" content="Abstracts/DLBCL-BULGARIA-DAVIDKOVA.html">
    <meta name="study:cancerTypes" content="DLBCL,LBCL,B-NHL">
    <meta name="study:lineOfTherapy" content="1L">
    <meta name="study:evidenceType" content="Real-world evidence">
    <meta name="study:drugs" content="Rituximab,Monoclonal Antibody,Polatuzumab Vedotin,ADC,Etoposide,Chemotherapy,CIT,R-CHOP,R-DA-EPOCH,Pola-R-CHP">

    <title>PB3326: DLBCL - Single Center Experience in Bulgaria (Davidkova) - SOBI Themed</title>
    <script src="https://cdn.tailwindcss.com"></script>
    <script src="https://d3js.org/d3.v7.min.js"></script>
    <link href="https://fonts.googleapis.com/css2?family=Inter:wght@400;600;700&display=swap" rel="stylesheet">
    <link rel="stylesheet" href="abstract_styles.css">
</head>
<body class="abstract-page-body">
    <div class="slide-container">
        <div class="visual-abstract-container">
            <h2 class="visual-abstract-title">Visual Summary: PB3326 - Diffuse large B-cell lymphoma - Single center experience in Bulgaria</h2>
            <div class="visual-abstract-grid">
                <div class="visual-abstract-item">
                    <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24" fill="var(--sobi-teal)"> <path d="M12 6.096c-1.058 0-2.02.468-2.704 1.248-.685.78-.996 1.788-.996 2.856s.311 2.076.996 2.856C9.98 13.84 10.942 14.31 12 14.31s2.02-.468 2.704-1.248.996-1.788.996-2.856-.311-2.076-.996-2.856C14.02 6.564 13.058 6.096 12 6.096zM12 12.81c-.53 0-1.008-.222-1.352-.588-.344-.366-.528-.852-.528-1.422s.184-1.056.528-1.422C10.992 9.012 11.47 8.79 12 8.79s1.008.222 1.352.588.528.852.528 1.422-.184-1.056-.528 1.422C13.008 12.588 12.53 12.81 12 12.81zm6.708 3.672A7.47 7.47 0 0012.024 15c-1.404 0-2.706.39-3.816 1.056A4.476 4.476 0 004.5 19.686V21h15v-1.314a4.476 4.476 0 00-3.792-3.624zM6.024 16.56c.84-.468 1.848-.768 2.904-.924A5.928 5.928 0 0112.024 15a5.928 5.928 0 013.096.636c1.056.156 2.064.456 2.904.924A2.988 2.988 0 0019.5 18.018V19.5h-15v-1.482a2.988 2.988 0 001.524-2.458zM4.5 7.032c0-1.068.312-2.076.996-2.856S7.2 3 8.256 3A7.47 7.47 0 0112.024 1.5c1.404 0 2.706.39 3.816 1.056A4.476 4.476 0 0119.5 6.186V7.5H4.5v-.468zM18 4.56c-.84.468-1.848-.768-2.904-.924A5.928 5.928 0 0012.024 6a5.928 5.928 0 00-3.096.636 7.524 7.524 0 00-2.904.924A2.988 2.988 0 014.5 7.482V6H3V4.5A1.5 1.5 0 014.5 3h15A1.5 1.5 0 0121 4.5V6h-1.5v1.482a2.988 2.988 0 01-1.524 2.458L18 4.56z" />
                    </svg>
                    <h4>Population & Aim (N=40)</h4>
                    <p>Newly diagnosed DLBCL (Bulgaria). Aim: Evaluate outcomes with R-CHOP, R-DA-EPOCH, Pola-R-CHP.</p>
                </div>
                <div class="visual-abstract-item">
                    <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24" fill="var(--sobi-teal)"> <path fill-rule="evenodd" d="M10.5 3.75a.75.75 0 01.75-.75h1.5a.75.75 0 01.75.75V4.5h3A2.25 2.25 0 0118.75 6.75v1.5a2.25 2.25 0 01-2.25 2.25H15.5V12h1.25a.75.75 0 010 1.5H15.5v1.5h.75a.75.75 0 010 1.5H15.5v1.5H18a.75.75 0 010 1.5h-2.5v1.5a.75.75 0 01-1.5 0V18h-1.5v1.5a.75.75 0 01-1.5 0V18h-1.5v1.5a.75.75 0 01-1.5 0v-3A2.25 2.25 0 016 14.25v-1.5A2.25 2.25 0 018.25 10.5H9.5V9H8.25A2.25 2.25 0 016 6.75v-1.5A2.25 2.25 0 018.25 3H10.5V3.75zm-1.5 6.75h6V6.75H9V10.5z" clip-rule="evenodd" />
                    </svg>
                    <h4>Intervention (1L Therapy)</h4>
                    <p>R-CHOP (45%), R-DA-EPOCH (37.5%), Pola-R-CHP (17.5%). Retrospective.</p>
                </div>
                <div class="visual-abstract-item">
                     <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24" fill="var(--sobi-orange)"> <path d="M3 13.5a.75.75 0 01.75-.75h16.5a.75.75 0 010 1.5H3.75A.75.75 0 013 13.5zM3 8.25a.75.75 0 01.75-.75h16.5a.75.75 0 010 1.5H3.75A.75.75 0 013 8.25zM3 18.75a.75.75 0 01.75-.75h16.5a.75.75 0 010 1.5H3.75A.75.75 0 013 18.75zM20.25 3a.75.75 0 00-.75.75v16.5a.75.75 0 001.5 0V3.75a.75.75 0 00-.75-.75z" />
                        <path fill-rule="evenodd" d="M9.97 4.28a.75.75 0 01.75-.75H12a.75.75 0 01.75.75v10.174l3.108-3.293a.75.75 0 111.084 1.038l-4.5 4.75a.75.75 0 01-1.084 0l-4.5-4.75a.75.75 0 111.084-1.038L9.97 14.454V4.28z" clip-rule="evenodd" />
                    </svg>
                    <h4>Key Efficacy (CR after 4 cycles)</h4>
                    <p>R-CHOP: <span class="highlight-value">59%</span><br>R-DA-EPOCH: <span class="highlight-value">23.5%</span><br>Pola-R-CHP: <span class="highlight-value">17.5%</span> (p=0.3). No OS/PFS diff (p=0.4).</p>
                </div>
                <div class="visual-abstract-item">
                    <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24" fill="var(--sobi-orange)"> <path fill-rule="evenodd" d="M12 2.25c-5.385 0-9.75 4.365-9.75 9.75s4.365 9.75 9.75 9.75 9.75-4.365 9.75-9.75S17.385 2.25 12 2.25zm-.092 14.444a.75.75 0 01-.092 0l-3.75-3.75a.75.75 0 111.06-1.06L12 14.813l3.182-3.182a.75.75 0 111.06 1.06l-3.75 3.75a.75.75 0 01-.53.22z" clip-rule="evenodd" />
                    </svg>
                    <h4>Conclusion</h4>
                    <p>Limited sample size; further prospective studies needed to distinguish prognostic markers and therapeutic options.</p>
                </div>
            </div>
        </div>

        <div class="text-center mb-8">
            <h1 class="abstract-header-title">PB3326 - Diffuse large B-cell lymphoma - Single center experience in Bulgaria</h1>
            <p class="abstract-sub-header">Yanitsa Davidkova, Naum Simonoski, Tanya Yankova, Martin Donchev</p>
            <p class="abstract-meta-info mt-2">EHA 2025 Congress | Abstract #PB3326 | Publication Only</p>
        </div>

        <div class="grid md:grid-cols-2 gap-x-8 gap-y-6">
            <div>
                <div class="abstract-card">
                    <h2 class="abstract-section-title">Background</h2>
                    <ul class="list-disc list-inside text-sm space-y-1 pl-2">
                        <li>The diffuse large B-cell lymphoma (DLBCL) is the most prevalent aggressive subtype of non-Hodgkin’s lymphoma.</li>
                        <li>For the last years standard of first line therapy was the regimen R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone).</li>
                        <li>However, according to the WHO classification DLBCL consists of heterogeneous entities based on molecular and prognostic characterization.</li>
                        <li>Therefore, diverse therapeutic options are emerging in order to enhance the clinical outcome.</li>
                    </ul>
                </div>

                <div class="abstract-card">
                    <h2 class="abstract-section-title">Aims</h2>
                    <p class="text-sm mb-1">The aim of the study was to evaluate newly diagnosed DLBCL patients treated with different therapeutic options R-CHOP, R-DA-EPOCH (dose adjusted etoposide, prednisone, vincristine, cyclophosphamide and doxorubicin) and pola-R-CHP (polatuzumab vedotin, rituximab, cyclophosphamide, doxorubicin, and prednisone).</p>
                </div>

                <div class="abstract-card">
                    <h2 class="abstract-section-title">Methods & Study Design</h2>
                    <ul class="list-disc list-inside text-sm space-y-1 mb-3 pl-2">
                        <li>Single-center retrospective cohort study (National Hematology Hospital, Bulgaria).</li>
                        <li>Patients: 40 consecutive, previously untreated DLBCL patients over a 2-year period.</li>
                        <li>Diagnosis: Established according to the WHO classification criteria. Immunohistochemistry performed locally.</li>
                        <li>Primary Endpoints: Overall survival (OS) and progression-free survival (PFS).</li>
                        <li>Statistical Analysis: Pearson’s Chi-test, Kaplan-Meier survival curves.</li>
                    </ul>
                     <div class="study-design-schema">
                        <h3 class="schema-title">Retrospective Study Overview</h3>
                        <div class="schema-enrollment">
                            <strong>Eligible Patients (N=40)</strong>
                            <span>Newly Diagnosed DLBCL</span>
                            <span>(Single Center, 2-year period)</span>
                        </div>
                        <div class="schema-arrow-down">▼</div>
                        <div class="schema-phase-group justify-around">
                            <div class="schema-phase" style="flex-basis: 32%; background-color: var(--sobi-light-teal-bg);">
                                <strong>R-CHOP (N=18, 45%)</strong>
                            </div>
                            <div class="schema-phase" style="flex-basis: 32%; background-color: var(--sobi-light-orange-bg);">
                                <strong>R-DA-EPOCH (N=15, 37.5%)</strong>
                            </div>
                             <div class="schema-phase" style="flex-basis: 32%; background-color: var(--sobi-light-gray-bg); border-color: var(--sobi-dark-blue);">
                                <strong>Pola-R-CHP (N=7, 17.5%)</strong>
                            </div>
                        </div>
                        <div class="schema-assessment-points">
                           <span>Response after 4 Cycles (CR)</span>
                           <span>Overall Survival (OS)</span>
                           <span>Progression-Free Survival (PFS)</span>
                        </div>
                    </div>
                </div>
            </div>

            <div>
                <div class="abstract-card">
                    <h2 class="abstract-section-title">Patient Characteristics (N=40)</h2>
                    <div class="table-container">
                        <table>
                            <thead>
                                <tr><th>Characteristic</th><th>Value</th></tr>
                            </thead>
                            <tbody>
                                <tr><td>Mean Age, years (range)</td><td>47.1 (19-67)</td></tr>
                                <tr><td>Female, n (%)</td><td>25 (62.5%)<sup>*</sup></td></tr>
                                <tr><td>IPI High-Intermediate/High, %</td><td>68% (High-Int: 44%, High: 24%)</td></tr>
                                <tr><td>Ann Arbor Stage III-IV, %</td><td>82.5%</td></tr>
                                <tr><td>Extranodal Involvement, %</td><td>70% (Mediastinum, GI, skin, bones, testis)</td></tr>
                                <tr><td>Bulky Disease, n (%)</td><td>14 (35%)</td></tr>
                                <tr><td>CD10 Expression, %</td><td>33%</td></tr>
                                <tr><td>BCL6 Expression, %</td><td>75%</td></tr>
                                <tr><td>BCL2 Expression, %</td><td>65%</td></tr>
                                <tr><td>c-myc Expression, n</td><td>5</td></tr>
                                <tr><td>Non-GC Phenotype, %</td><td>>33% (GCB 33%)</td></tr>
                                <tr><td>Double/Triple-Hit Lymphoma, n</td><td>5 (DH=1, TH=4)</td></tr>
                                <tr><td>Double-Expressor Lymphoma, %</td><td>~50% ("half of all patients")</td></tr>
                                <tr><td>High Ki-67 (≥80%), %</td><td>22%</td></tr>
                            </tbody>
                        </table>
                        <p class="footnote-text mt-1"><sup>*</sup>Abstract states 37.5% female, but 25/40 calculates to 62.5%.</p>
                    </div>
                </div>

                <div class="abstract-card">
                    <h2 class="abstract-section-title">Efficacy Results by Treatment Regimen</h2>
                     <p class="text-sm mb-2"><strong>Patient Distribution by Regimen:</strong></p>
                    <ul class="list-disc list-inside text-sm space-y-1 pl-2 mb-3">
                        <li>R-CHOP: N=18 (45%)</li>
                        <li>R-DA-EPOCH: N=15 (37.5%)</li>
                        <li>Pola-R-CHP: N=7 (17.5%)</li>
                    </ul>
                     <p class="text-sm mb-2"><strong>Baseline Differences between Regimens:</strong></p>
                     <ul class="list-disc list-inside text-sm space-y-1 pl-2 mb-3">
                        <li>Mean Age: R-DA-EPOCH significantly younger (37.9y) vs R-CHOP (54.6y) & Pola-R-CHP (47.6y) (p=0.003).</li>
                        <li>Bulky Disease: 71% in R-DA-EPOCH vs 28.6% in R-CHOP & 0% in Pola-R-CHP (p=0.002).</li>
                        <li>IPI High-Int/High: R-CHOP (80%) vs R-DA-EPOCH (67%) vs Pola-R-CHP (50%).</li>
                    </ul>
                    <div class="chart-container mb-6">
                        <svg id="dlbclBulgariaCRChart" width="400" height="300"></svg>
                        <div id="dlbclBulgariaCRLegend" class="legend"></div>
                    </div>
                    <p class="text-sm mb-2"><strong>CR Rate after 4 Cycles:</strong></p>
                    <ul class="list-disc list-inside text-sm space-y-1 pl-2 mb-3">
                        <li>R-CHOP: 59%</li>
                        <li>R-DA-EPOCH: 23.5%</li>
                        <li>Pola-R-CHP: 17.5%</li>
                        <li>(p=0.3, not significant)</li>
                    </ul>
                     <p class="text-sm mb-2"><strong>Progression after 4 Cycles:</strong></p>
                     <ul class="list-disc list-inside text-sm space-y-1 pl-2 mb-3">
                        <li>R-CHOP: 1 patient</li>
                        <li>R-DA-EPOCH: 3 patients</li>
                        <li>Pola-R-CHP: 1 patient</li>
                    </ul>
                    <p class="text-sm">No significant difference in OS or PFS between the three regimens (p=0.4).</p>
                </div>
                 <div class="abstract-card">
                    <h2 class="abstract-section-title">Safety Summary</h2>
                     <p class="text-sm">Safety data (adverse events) were not detailed in this abstract text.</p>
                </div>
            </div>
        </div>

        <div class="abstract-card mt-6">
            <h2 class="abstract-section-title">Summary & Conclusion</h2>
            <ul class="list-disc list-inside text-sm space-y-1 pl-2">
                <li>Because of limited sample size of the investigated cohort, further prospective studies are required in order to distinguish feasible prognostic markers related to therapeutic options.</li>
            </ul>
        </div>

        <div class="abstract-card mt-6 abbreviations-list">
            <h2 class="abstract-section-title">Abbreviations</h2>
            <p>ADC, Antibody-Drug Conjugate; AE, Adverse Event; BCL2, B-cell lymphoma 2; BCL6, B-cell lymphoma 6; CHEMO, Chemotherapy; CIT, Chemoimmunotherapy; CR, Complete Remission; DLBCL, Diffuse Large B-Cell Lymphoma; EPOCH, Etoposide, Prednisone, Vincristine, Cyclophosphamide, Doxorubicin; GCB, Germinal Center B-cell like; GI, Gastrointestinal; IPI, International Prognostic Index; NHL, Non-Hodgkin Lymphoma; OS, Overall Survival; PFS, Progression-Free Survival; Pola-R-CHP, Polatuzumab vedotin, Rituximab, Cyclophosphamide, Doxorubicin, Prednisone; R-CHOP, Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone; R-DA-EPOCH, Rituximab, Dose-Adjusted Etoposide, Prednisone, Vincristine, Cyclophosphamide, Doxorubicin; WHO, World Health Organization.</p>
        </div>

        <div class="abstract-card mt-6 reference-section">
            <h2 class="abstract-section-title">
                Reference
                <button id="copyReferenceBtn" class="copy-reference-button" title="Copy Reference">
                    <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor">
                        <path d="M7 3.5A1.5 1.5 0 018.5 2h3.879a1.5 1.5 0 011.06.44l3.122 3.121A1.5 1.5 0 0117 6.621V16.5a1.5 1.5 0 01-1.5 1.5h-7A1.5 1.5 0 017 16.5v-13z" />
                        <path d="M4.5 6A1.5 1.5 0 003 7.5v10A1.5 1.5 0 004.5 19h7a1.5 1.5 0 001.5-1.5v-2.5a.75.75 0 00-1.5 0v2.5a.5.5 0 01-.5.5h-7a.5.5 0 01-.5-.5v-10a.5.5 0 01.5-.5h2.5a.75.75 0 000-1.5H4.5z" />
                    </svg>
                    Copy
                </button>
            </h2>
            <p id="referenceSectionContent">
Davidkova Y, Simonoski N, Yankova T, et al. Diffuse Large B-Cell Lymphoma - Single center experience in Bulgaria. Abstract #PB3326 presented at European Haematology Association (EHA) June 12–15, 2025, Milan, Italy.
            </p>
        </div>

        <div class="abstract-footer-info">
            <p>EHA 2025 Congress | Abstract #PB3326 | Abstract Release: 05/14/25 | Publication Only: 06/12/2025</p>
            <p>For Research & Informational Purposes Only.</p>
        </div>
    </div>

    <script defer src="abstract_features.js"></script>
    <script>
        function drawCrRateChartPB3326(containerId, legendContainerId) {
            const chartTitle = "CR Rate after 4 Cycles by Regimen";
            const chartData = [
                { group: "R-CHOP (N=18)", value: 59.0 },
                { group: "R-DA-EPOCH (N=15)", value: 23.5 },
                { group: "Pola-R-CHP (N=7)", value: 17.5 }
            ];
            const pValue = 0.3; 

            const svg = d3.select(containerId);
            const legendContainer = d3.select(legendContainerId);

            svg.selectAll("*").remove();
            legendContainer.selectAll("*").remove();

            let containerWidth = 400;
            const chartWrapper = svg.node() ? svg.node().closest('.chart-container') : null;
            if (chartWrapper) {
                containerWidth = Math.max(chartWrapper.getBoundingClientRect().width * 0.9, 300);
            }
            
            const svgWidth = containerWidth;
            const svgHeight = +svg.attr("height");

            const margin = { top: 50, right: 20, bottom: 70, left: 60 };
            const chartWidth = svgWidth - margin.left - margin.right;
            const chartHeight = svgHeight - margin.top - margin.bottom;

            if (chartWidth <= 0 || chartHeight <=0) return;

            const g = svg.append("g")
                .attr("transform", `translate(${margin.left},${margin.top})`);

            const groups = chartData.map(d => d.group);
            
            const xScale = d3.scaleBand()
                .domain(groups)
                .range([0, chartWidth])
                .padding(0.3);

            const yScale = d3.scaleLinear()
                .domain([0, 100]) 
                .range([chartHeight, 0]);

            const colorScale = d3.scaleOrdinal()
                .domain(groups)
                .range(["var(--sobi-teal)", "var(--sobi-orange)", "var(--sobi-yellow)"]);

            g.append("g")
                .attr("transform", `translate(0,${chartHeight})`)
                .call(d3.axisBottom(xScale))
                .selectAll("text")
                .attr("class", "axis-text")
                .style("font-size", "10px")
                .attr("transform", "rotate(-10) translate(-2,0)")
                .style("text-anchor", "end");

            g.append("g")
                .call(d3.axisLeft(yScale).ticks(5).tickFormat(d => d.toFixed(0) + "%"))
                .selectAll("text")
                .attr("class", "axis-text")
                .style("font-size", "10px");

            g.append("g")			
                .attr("class", "grid")
                .call(d3.axisLeft(yScale)
                    .ticks(5)
                    .tickSize(-chartWidth)
                    .tickFormat("")
                )
                .selectAll("line")
                .style("stroke", "#e0e0e0")
                .style("stroke-opacity", "0.7");

            g.selectAll(".bar")
                .data(chartData)
                .enter().append("rect")
                  .attr("class", "bar")
                  .attr("x", d => xScale(d.group))
                  .attr("y", d => yScale(d.value))
                  .attr("width", xScale.bandwidth())
                  .attr("height", d => chartHeight - yScale(d.value))
                  .attr("fill", d => colorScale(d.group))
                  .attr("rx", 3).attr("ry", 3);
            
            g.selectAll(".bar-label")
                .data(chartData)
                .enter().append("text")
                .attr("class", "chart-label")
                .attr("x", d => xScale(d.group) + xScale.bandwidth() / 2)
                .attr("y", d => yScale(d.value) - 5) 
                .attr("text-anchor", "middle")
                .style("font-size", "10px")
                .style("fill", "var(--sobi-dark-text)")
                .text(d => `${d.value.toFixed(1)}%`);
            
            svg.append("text")
                .attr("x", svgWidth / 2)
                .attr("y", margin.top / 2)
                .attr("text-anchor", "middle")
                .style("font-size", "14px")
                .style("font-weight", "600")
                .style("fill", "var(--sobi-dark-blue)")
                .text(chartTitle);

            svg.append("text")
                .attr("x", svgWidth / 2)
                .attr("y", chartHeight + margin.top + 45)
                .attr("text-anchor", "middle")
                .style("font-size", "10px")
                .style("font-weight", pValue < 0.05 ? "bold" : "normal")
                .style("fill", pValue < 0.05 ? "var(--sobi-orange)" : "var(--sobi-dark-text)")
                .text(`P = ${pValue.toFixed(1)}`);
                
            const legendData = chartData.map(d => ({
                label: `${d.group} (CR: ${d.value.toFixed(1)}%)`, // Include CR rate in legend
                color: colorScale(d.group)
            }));

            const legendItems = legendContainer.selectAll(".legend-item")
                .data(legendData).enter().append("div").attr("class", "legend-item");
            legendItems.append("div").attr("class", "legend-color-box").style("background-color", d => d.color);
            legendItems.append("span").text(d => d.label);
        }
        
        function debounce(func, wait) {
            let timeout;
            return function executedFunction(...args) {
                const later = () => {
                    clearTimeout(timeout);
                    func(...args);
                };
                clearTimeout(timeout);
                timeout = setTimeout(later, wait);
            };
        };

        const debouncedDrawPB3326Chart = debounce(() => drawCrRateChartPB3326("#dlbclBulgariaCRChart", "#dlbclBulgariaCRLegend"), 250);
        
        window.addEventListener('resize', debouncedDrawPB3326Chart);
        
        document.addEventListener('DOMContentLoaded', () => {
            debouncedDrawPB3326Chart();
        });
        if (document.readyState === "complete" || document.readyState === "interactive") {
             setTimeout(debouncedDrawPB3326Chart, 0); 
        }
    </script>
</body>
</html>